Related references
Note: Only part of the references are listed.Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US
Rohini K. Hernandez et al.
SUPPORTIVE CARE IN CANCER (2014)
Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
Daniel C. McFarland et al.
ONCOTARGETS AND THERAPY (2014)
Clinical usefulness of bone markers in prostate cancer with bone metastasis
Naoto Kamiya et al.
INTERNATIONAL JOURNAL OF UROLOGY (2012)
Single-stage posterior decompression and stabilization for metastasis of the thoracic spine: prognostic factors for functional outcome and patients' survival
Sangjoon Chong et al.
SPINE JOURNAL (2012)
Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors
Hui Zhao et al.
MEDICAL SCIENCE MONITOR (2011)
Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma
Yorihisa Orita et al.
THYROID (2011)
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
S. Rajpar et al.
ANNALS OF ONCOLOGY (2010)
Comparison of biochemical markers of bone turnover in paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links
A.G. Randall et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma
Yorihisa Orita et al.
SURGERY (2010)
The Pharmacological Management of Skeletal-Related Events From Metastatic Tumors
Anna Hitron et al.
ORTHOPEDICS (2009)
Bisphosphonate use and the risk of adverse jaw outcomes
Vassiliki M. Cartsos et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2008)
Papillary thyroid carcinoma with distant metastases: Survival predictors and the importance of local control
Iwao Sugitani et al.
SURGERY (2008)
Zoledronic acid and survival in breast cancer patients with bone Metastases and elevated markers of osteoclast activity
Allan Lipton et al.
ONCOLOGIST (2007)
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases
Giovanni Storto et al.
BONE (2006)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status
L Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Novel therapeutic approaches to cancer patients with bone metastasis
R Maisano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
G Vitale et al.
BRITISH JOURNAL OF CANCER (2001)
Share Paper
